Company intelligence / Profile preview

Onselex Pharmaceuticals

New York, New York, United Statesonselex.com ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

Onselex has developed ONX‑1006, a non-toxic nanomedicine that induces apoptosis in tumor cells with minimal side effects. The company claims this could reduce pancreatic cancer death rates and achieve a 70% five-year survival rate. Human trials are being planned in Argentina to accelerate regulatory approval.

No published clinical results yet; preclinical data suggest high efficacy and safety.

Therapeutic areas: Oncology
Modalities: Nanomedicinenanoparticle-loaded therapeutics
Industry: Biotech

Drug pipeline

3 assets

ONX-1106

Preclinical

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Onselex Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onselex Pharmaceuticals.

Explore the full profile